secwatch.observer — SEC 8-K summary
======================================

Issuer:     Philip Morris International Inc. (PM)
CIK:        0001413329
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001413329-24-000160
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMI agrees to sell Vectura Group to Molex for up to GBP 298M; expects ~$220M Q3 loss
--------------------------------------------------------------------------------

- Upfront cash consideration of GBP 150M (~$198M) plus up to GBP 148M in contingent milestone payments through 2039.
- Transaction expected to close by end of 2024, subject to regulatory approval and customary closing conditions.
- PMI expects to record an estimated loss of ~$220M in Q3 2024 on the sale, subject to working capital adjustments.
- PMI cites unwarranted opposition to its ownership as reason for sale; remaining Vectura Fertin Pharma units to continue under new identity.
- Vectura will be operated by Phillips Medisize (Molex), focusing on inhalation drug delivery and CDMO services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1413329/000141332924000160/0001413329-24-000160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1413329/000141332924000160/pm-20240917.htm
  HTML page:      https://secwatch.observer/filing/0001413329-24-000160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer